1037254-47-9 Usage
General Description
MK-1496, also known as guadecitabine, is a next-generation hypomethylating agent that has demonstrated potential as a treatment for various types of cancer. The chemical is a dinucleotide of decitabine and deoxyguanosine that forms within cells after oral or intravenous administration. It works by incorporating into DNA and inhibiting DNA methyltransferase, ultimately leading to the demethylation of DNA and reactivation of tumor suppressor genes. Preclinical studies have shown promising antileukemic activity, and clinical trials are underway to evaluate its efficacy in treating myelodysplastic syndromes, acute myeloid leukemia, and other solid tumors. MK-1496 has the potential to offer a new treatment option for patients with various types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 1037254-47-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,7,2,5 and 4 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1037254-47:
(9*1)+(8*0)+(7*3)+(6*7)+(5*2)+(4*5)+(3*4)+(2*4)+(1*7)=129
129 % 10 = 9
So 1037254-47-9 is a valid CAS Registry Number.
1037254-47-9Relevant articles and documents
NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS
-
Page/Page column 66, (2008/12/07)
The present invention relates to a compound represented by Formula [I]: or a pharmaceutically acceptable salt or ester thereof, wherein R1 and R2, which may be the same or different, are each a hydrogen atom, a halogen atom, a lower
